Many years of dedication to your success

DxOrange is a trusted provider of strategic consulting services for the global biotech industry. DxOrange B.V., founded by Dr. Jan Groen in 2009, is a first class service provider for stakeholders in the biotech world-wide and has a wide network of partners and professionals.

 

Experience Excellence Expertise in healthcare, life sciences, and technology

  • C-Level executives for strategies, advice, and consultancy.
  • Start ups, Series B, C or D funded and public companies.
  • Reimbursement
  • Duediligence & technology assessments
  • Mergers and acquisitions 
  • Assessments of and guidance from Research & Development to market positioning 

 

Dr. Jan Groen

Jan is an expert in the biotech industry, with a particular focus on strategy, emerging technologies, product development and commercialization. He has a strong R&D background, and experience with mergers, acquisitions, fund raising, investor relations, restructuring and performance optimization. Jan holds a Ph.D. degree in Medical Microbiology from the Erasmus University Rotterdam, a BSc in Clinical Laboratory Studies and has published over 125 papers in international scientific journals in the biotech.

 

Dr. Jan Groen

Founder & CEO DxOrange

Jan Groen CEO and owner of DXOrange B.V.  is currently engaged in various C-level advisory roles and board positions within the bioscience industry. During his tenure as CEO of Intravacc from 2019 to 2024, he oversaw the transformation of the vaccine research institute, previously under the Ministry of Health, Welfare, and Sport, into an independent entity with the Dutch State as a shareholder. Under his leadership, Intravacc successfully secured numerous grant projects, including a significant commercial project for a bladder cancer vaccine, and completed a human phase 1 clinical trial for an intranasal vaccine. As a result, Intravacc has emerged as a respected player in the CDMO market. In April 2024, Intravacc was acquired by FDI Biosciences in the Netherlands.

Prior to his role at Intravacc, Jan served as CEO of Novigenix, a Swiss ImmunoTranscriptomic biotech company, and spent nine years as CEO of MDxHealth. In 2010, he spearheaded the rebranding of Oncomethylome, a small Belgian biotech, into 'MDxHealth,' which subsequently became a leading uro-oncology molecular diagnostics company in the US and EU, boasting several diagnostic products on the market. Earlier in his career, he held the position of president and COO at Agendia, a breast cancer diagnostics company, overseeing diagnostic operations in the United States and Europe. Jan also served as VP of Research & Development at Focus Diagnostics, a subsidiary of Quest Diagnostics based in California. Furthermore, he is a co-founder of ViroClinics B.V., an infectious disease company. He has held various management and scientific positions at the Erasmus Medical Center, the National Institute for Public Health (NL), and Akzo-Nobel. Additionally, Jan served on the boards of IBL-International (G) and MyCartis (B).

Current Assignments

  • Board member & chairman at Angle PLc (UK)
  • CEO at Ceravx B.V. (NL)
  • Chief Strategic Officer at GetFueled B.V.(NL)
  • Board member & chairman at Vesica Health (USA)
  • Board member Delta Diagnostics (NL)
  • Board member at Novigenix (CH)
  • Board member at SPL Medical B.V. (NL)
  • Strategic advisor to CanHelp Genomics (China)
  • Strategic advisor to Pamgene (NL)
  • Investment advisor to Oncode (NL)
  • Advisor to CRCbioscreen (NL)
  • Advisor to Levels Diagnostics (NL)
  • Steering Committee VitroScan NL) 

Selected Accomplishments

  • Raised over $150 million for private and public companies
  • Acquisition of diagnostic companies
  • Successfully structured and directed a turn around strategy of companies in distress
  • Directly involved with a successful M&A process of two IVD companies (2006 and 2014)
  • Built several successful commercial diagnostic companies in Europe and the USA
  • Develop and launched CE and FDA cleared diagnostic products
  • Transformed a research institute into an independent entity.

    •      Vaccine development for Corona (COVID 19) 

    Podcasts & Videos